SAFETY IMPLICATIONS OF THE OVER-THE-COUNTER AVAILABILITY OF H-2-ANTAGONISTS

Andersen M., Schou J.S., Bivirkninger af ulcusmedicin for og efter overførsel af cimetidin, ranitidin og sukralfat til håndkøb (Adverse reactions to peptic ulcer medicine before and after cimetidine, ranitidine and sucralfate became available over-the-counter), Ugeskrift for Laeger, 153, pp. 1410-1413, (1991)

Andersen M., Schou J.S., Adverse reactions to H₂-receptor antagonists in Denmark before and after transfer of cimetidine and ranitidine to over-the-counter status, Pharmacology and Toxicology, 69, pp. 253-258, (1991)

Aymard J.-P., Aymard B., Netter P., Bannwarth B., Trechot P., Et al., Haematological adverse effects of histamine H₂-receptor antagonists, Medical Toxicology, 3, pp. 430-448, (1988)

Brown C., Rees W.D.W., Dyspepsia in general practice, British Medical Journal, 300, pp. 829-830, (1990)

Bytzer P., Hansen J.M., Schaffalitzky de Muckadell O.B., Overførsel af potent ulcusmedicin til håndkøb: en undersøgelse af aendringer i forbrugsmønstret og i presset på de diagnostiske tilbud (Over-the-counter availability of potent ulcer drugs: study of changes in the drug use pattern and the pressure on diagnostic measures), Ugeskrift for Laeger, 153, pp. 1405-1410, (1991)

Colin-Jones D.G., Acid suppression: how much is needed?, British Medical Journal, 301, pp. 564-565, (1990)

Colin-Jones D.G., Bloom B., Bodemar G., Management of dyspepsia: report of a working party, Lancet, 1, pp. 576-579, (1988)

Colin-Jones D.G., Langman M.J.S., Lawson D.H., Logan R.F.A., Paterson K.A., Et al., Post-cimetidine surveillance for up to ten years: incidence of carcinoma of the stomach and oesophagus, Quarterly Journal of Medicine, 78, pp. 13-19, (1991)

Colin-Jones D.G., Langman M.J.S., Lawson D.H., Vessey M.P., Post-marketing surveillance of the safety of cimetidine: mortality during second, third and fourth years of follow-up, British Medical Journal, 291, pp. 1084-1088, (1985)

Cranz H., Over-the-counter drugs: the issues, Drug Safety, 5, pp. 120-125, (1990)

Andersen M., Schou J.S., Bivirkninger af ulcusmedicin for og efter overførsel af cimetidin, ranitidin og sukralfat til håndkøb (Adverse reactions to peptic ulcer medicine before and after cimetidine, ranitidine and sucralfate became available over-the-counter), Ugeskrift for Laeger, 153, pp. 1410-1413, (1991)

Andersen M., Schou J.S., Adverse reactions to H₂-receptor antagonists in Denmark before and after transfer of cimetidine and ranitidine to over-the-counter status, Pharmacology and Toxicology, 69, pp. 253-258, (1991)

Aymard J.-P., Aymard B., Netter P., Bannwarth B., Trechot P., Et al., Haematological adverse effects of histamine H₂-receptor antagonists, Medical Toxicology, 3, pp. 430-448, (1988)

Brown C., Rees W.D.W., Dyspepsia in general practice, British Medical Journal, 300, pp. 829-830, (1990)

Bytzer P., Hansen J.M., Schaffalitzky de Muckadell O.B., Overførsel af potent ulcusmedicin til håndkøb: en undersøgelse af aendringer i forbrugsmønstret og i presset på de diagnostiske tilbud (Over-the-counter availability of potent ulcer drugs: study of changes in the drug use pattern and the pressure on diagnostic measures), Ugeskrift for Laeger, 153, pp. 1405-1410, (1991)

Colin-Jones D.G., Acid suppression: how much is needed?, British Medical Journal, 301, pp. 564-565, (1990)

Colin-Jones D.G., Bloom B., Bodemar G., Management of dyspepsia: report of a working party, Lancet, 1, pp. 576-579, (1988)

Colin-Jones D.G., Langman M.J.S., Lawson D.H., Logan R.F.A., Paterson K.A., Et al., Post-cimetidine surveillance for up to ten years: incidence of carcinoma of the stomach and oesophagus, Quarterly Journal of Medicine, 78, pp. 13-19, (1991)

Colin-Jones D.G., Langman M.J.S., Lawson D.H., Vessey M.P., Post-marketing surveillance of the safety of cimetidine: mortality during second, third and fourth years of follow-up, British Medical Journal, 291, pp. 1084-1088, (1985)

Cranz H., Over-the-counter drugs: the issues, Drug Safety, 5, pp. 120-125, (1990)